A5028612075- Cancer Immunotherapy and Biomarkers
- Endometrial and Cervical Cancer Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Cervical Cancer and HPV Research
- Renal cell carcinoma treatment
- Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Polyomavirus and related diseases
Universidad de La Frontera
1999-2025
Universidad Andrés Bello
2024
Petroleum of Venezuela (Venezuela)
1999
94 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) mismatch repair (MMR) deficient colorectal cancer, both as first-line and after progression following fluoropyrimidine, oxaliplatin, irinotecan. The combination lenvatinib, a multiple receptor tyrosine kinase inhibitor, showed synergistic antitumor activity in preclinical models. LEAP-005 (NCT03797326) evaluating...
The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy or without bevacizumab in patients persistent, recurrent, metastatic cervical cancer. Treatment effects patient subgroups study population are unknown.
Len (antiangiogenic multiple receptor tyrosine kinase inhibitor) + pembro (anti‒PD-1 agent) showed promising clinical outcomes across several cancers in early-phase trials and is FDA-approved for pts with previously treated advanced endometrial cancer that not MSI-H or mismatch repair-deficient who are ineligible curative surgery/radiation. We report the first results from phase 2 LEAP-005 study (NCT03797326), which evaluates efficacy safety of len select solid tumors. This open-label,...
321 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination the programmed death-1 immune checkpoint inhibitor pembrolizumab, has demonstrated promising antitumor activity a manageable safety profile select advanced solid tumors. LEAP-005 (NCT03797326) is evaluating efficacy and of lenvatinib plus pembrolizumab previously treated tumors; here we present results from BTC cohort...
Abstract Background Novel treatments are needed for patients with advanced, triple‐negative breast cancer (TNBC) that progresses or recurs after first‐line treatment chemotherapy. The authors report results from the TNBC cohort of multicohort, open‐label, single‐arm, phase 2 LEAP‐005 study lenvatinib plus pembrolizumab in advanced solid tumors (ClinicalTrials.gov identifier NCT03797326). Methods Eligible had metastatic unresectable disease progression one two lines therapy. Patients received...
5500 Background: The first interim analysis of KEYNOTE-826 (NCT03635567) showed that first-line pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant and clinically meaningful improvements in OS PFS vs placebo (pbo) chemo patients (pts) with recurrent, persistent, or metastatic cervical cancer across all prespecified populations (PD-L1 combined positive score [CPS] ≥1, all-comer, CPS ≥10). Here, we present the protocol-specified final results KEYNOTE-826. Methods:...
4080 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination the programmed death-1 immune checkpoint inhibitor pembrolizumab, has demonstrated promising antitumor activity a manageable safety profile select advanced solid tumors. LEAP-005 (NCT03797326) is evaluating efficacy and of lenvatinib plus pembrolizumab previously treated tumors; here we present results from BTC cohort...
5563 Background: ctDNA is a promising biomarker for predicting disease progression, survival, and surgical outcomes in patients with solid tumors. In phase 1 study (NCT03564691), ILT4 inhibitor MK-4830 + pembro had manageable safety profile showed antitumor activity pts We present results from global, randomized 2 (NCT05446870) evaluating quantitative change high-grade serous ovarian cancer (HGSOC) who received neoadjuvant chemo ± MK-4830. Methods: Eligible were female, aged ≥18 y,...
3564 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) mismatch repair (MMR) deficient colorectal cancer, both as first-line and after progression following fluoropyrimidine, oxaliplatin, irinotecan. The combination lenvatinib, a multiple receptor tyrosine kinase inhibitor, showed synergistic antitumor activity in preclinical models. LEAP-005 (NCT03797326)...
230 Background: Lenvatinib, an anti-angiogenic multiple receptor tyrosine kinase inhibitor, in combination with the anti‒PD-1 antibody pembrolizumab, has demonstrated promising antitumor activity manageable safety first- or second-line a phase 2 trial of patients advanced gastric cancer. LEAP-005 (NCT03797326) is 2, multicohort, nonrandomized, open-label study evaluating efficacy and lenvatinib plus pembrolizumab previously treated solid tumors; here, we present findings from cancer cohort...
PF-05280014 was compared with trastuzumab sourced from the European Union (trastuzumab-EU), each plus paclitaxel, as first-line treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer in a phase III study. Equivalence between groups demonstrated. The aim of this study to report long-term safety and overall survival (OS) over 6 years after first patient screened. Randomized patients received intravenous or trastuzumab-EU, until objective disease progression....
5506 Background: In KEYNOTE-826 (NCT03635567),pembrolizumab (pembro) + chemotherapy (chemo) ± bevacizumab (bev) provided statistically significant, clinically meaningful PFS and OS improvements in patients with persistent, recurrent, or metastatic cervical cancer. the present analysis of KEYNOTE-826, we assessed outcomes several key patient subgroups. Methods: Eligible adult had squamous cell carcinoma, adenosquamous adenocarcinoma cervix not previously treated chemo amenable to curative...
Gallbladder cancer is generally associated with a poor prognosis, local recurrence being the main pattern of failure. In an attempt to improve on present status management, we evaluated prospective Phase II study involving preoperative 5-fluorouracil and radiation. Among 27 eligible patients potentially resectable gallbladder detected after cholecystectomy, 18 were treated radiation (4500 cGy; 180 cGy/fraction, 5 days/week) concurrent continuous infusion (350 mg/m2/day, days 1-5 21-25)....
<h3>Introduction/Background</h3> In KEYNOTE-826 (NCT03635567), pembrolizumab (pembro) + chemotherapy (chemo) ± bevacizumab (bev) provided statistically significant and clinically meaningful overall survival (OS) progression-free (PFS) improvements in patients with persistent, recurrent, or metastatic cervical cancer. the present exploratory analysis, we examined treatment outcomes patient subgroups defined by bev use. <h3>Methodology</h3> Eligible adult had squamous cell carcinoma,...
Abstract Background: Triple-negative breast cancer (TNBC) is associated with poor survival outcomes and treatment options are limited. These tumors lack therapeutic targets become rapidly resistant to chemotherapy. The anti–PD-1 antibody pembrolizumab showed durable antitumor activity manageable safety in patients TNBC the KEYNOTE-012, KEYNOTE-086, KEYNOTE-119 studies. combination of lenvatinib, an antiangiogenic multiple receptor tyrosine kinase inhibitor, has shown promising clinical...
TPS5619 Background: Oregovomab, a murine IgGκ1 monoclonal antibody, has high affinity binding to tumor associated antigen CA125, thus, rendering the target CA125 more immunogenic or “neoantigen-like” through altered and enhanced processing presentation specific T cells. This phenomenon is hypothesized bypass tumor-associated immune suppression when oregovomab combined with chemotherapy. In randomized phase II study, in combination paclitaxel carboplatin (PC) induced immunity demonstrated...
<h3>Introduction/Background</h3> The first interim analysis of KEYNOTE-826 (NCT03635567) showed that first-line pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant and clinically meaningful improvements in OS PFS vs placebo (pbo) chemo patients (pts) with recurrent, persistent, or metastatic cervical cancer across all prespecified populations (PD-L1 combined positive score [CPS] ≥1, all-comer, CPS ≥10). Here, we present the protocol-specified final results...